Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, announces that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17–21. Preliminary results show a favorable safety profile within the investigated activity range and sustained…
Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or 177Lu) to support the development of 177Lu-AKIR001 (AKIR001), a targeted antibody-radionuclide conjugate with first-in-class potential, currently in clinical testing for the…
Akiram Therapeutics, a Swedish biotech company specializing in molecular radiotherapy, announces that new preclinical data on its lead candidate AKIR001 have been published in The Journal of Nuclear Medicine. The results demonstrate selective tumor uptake, clear antitumor effects, and favorable tolerability in preclinical pancreatic cancer models, further strengthening the scientific foundation for AKIR001. The article…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that cohort 2b in the ongoing Phase I clinical trial evaluating the drug candidate 177Lu-AKIR001 has been completed. Following the safety review, the study has advanced to cohort 3. The results continue to support a favorable safety profile, enabling further dose escalation and evaluation of…
The preclinical study underpinning the clinical development of Akiram Therapeutics’ lead candidate AKIR001, published in The Journal of Nuclear Medicine (JNM), has been selected as best basic investigation and overall featured article for the February issue. An image from the article also appears on the cover. AKIR001 is developed by Akiram Therapeutics, a Swedish biotech…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. Cohort 2a investigated a higher activity dose than the run-in cohort. The results aligned with earlier findings, demonstrating continued favorable safety and encouraging tumor uptake. The trial is…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that data on its CD44v6-targeted radiotherapeutic candidate AKIR001 have been published in The Journal of Nuclear Medicine, one of the leading journals in nuclear medicine. The publication summarizes key studies underpinning the ongoing first-in-human Phase 1 trial at Karolinska University Hospital. It reports high…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October 4–8. Two have been selected as Top Rated Oral Presentations, highlighting continued development of the CD44v6-targeting antibody used in the company’s clinical-stage radiopharmaceutical—currently being investigated in a Phase I clinical trial….
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of the first cohort in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. No safety signals have been observed, and the trial is now proceeding to the next stage as planned. The trial is being conducted at Karolinska University Hospital,…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts to…